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Abstract
Background: Neuropilin-1 (NRP-1) is a transmembrane glycoprotein participating in the growth and metastasis of
cancer cells as multifunctional co-receptors by interacting with the signaling pathways. However, its role in gastric
cancer has not yet been clarified. This study aims to investigate whether NRP-1 expression is associated with the
clinicopathology of gastric cancer, and involved in the growth and metastasis of gastric cancer cells.
Methods: NRP-1 expression in clinical gastric cancer specimens was examined by immunohistochemistry and its
association with clinicopathology analyzed. The expression of NRP-1 in a panel of human gastric cancer cells was
examined by real-time RT-PCR and immunoblotting. Stable transfectants depleted of NRP-1, termed MGC-803-NRPlow,
were generated from MGC-803 cells. Cell proliferation was analyzed by the Cell Counting Kit-8 and Bromodeoxyuridine
incorporation assays, and migrating ability analyzed by migration assays. The xenograft model was used to assess the
effects of NRP-1 depletion on tumorigenesis, growth, metastasis and therapeutic potentials. The role of NRP-1 as
co-receptors in the signaling pathways stimulated by ligands was examined. The key molecules involved in cell
proliferation, migration and related signaling pathways were detected by immunoblotting.
Results: Gastric cancer tissues expressed higher levels of NRP-1 compared to normal gastric mucosa. Its expression
correlated with clinical staging, tumor differentiation and pathological types. NRP-1 depletion inhibited cell proliferation
by inducing cell cycle arrest in the G1/S phase by upregulating p27, and downregulating cyclin E and cyclin-dependent
kinase 2. NRP-1 depletion reduced the ability of cells to migrate by inhibiting the phosphorylation of focal adhesion
kinase. NRP-1 depletion suppressed tumorigenesis, tumor growth and lung metastasis by inhibiting cell proliferation and
tumor angiogenesis in situ. Therapeutic NRP-1 shRNA inhibited the growth of established BGC823 tumors. Depletion of
NRP-1 inhibited the activation of VEGF/VEGFR2, EGF/EGFR and HGF/c-Met pathways stimulated by respective
recombinant human VEGF-165, EGF and HGF proteins.
Conclusions: The present results indicate that NRP-1 may be a potentially valuable biomarker and therapeutic target for
gastric cancer.
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Background
Neuropilin-1 (NRP-1), a transmembrane glycoprotein,
was initially identified as a neuronal receptor for the
class 3 semaphorins [1]. It is now known that NRP-1
also acts as multifunctional co-receptors participating in
the initiation, growth and metastasis of cancer cells [1].
NRP-1 is overexpressed in several common types of can-
cer. More importantly, NRP-1 expression associates with
the advanced stage of disease, and negatively correlates
with the prognosis of hepatocellular carcinoma [2], colo-
rectal cancer [3], and esophagus squamous cell carcin-
oma [4], indicating that NRP-1 is a potential molecular
target for cancer therapy. Specific inhibition of NRP-1
has been shown to suppress the growth and metastasis
of several types of cancer cells [5–9].
The mechanisms for the role of NRP-1 in cancer pro-
gression rely on its interactions with several key signal-
ing pathways in cancer cells. NRP-1 interacts with
vascular endothelial growth factor (VEGF) and its recep-
tor VEGFR2, leading to the activation of this pathway
and promoting tumor angiogenesis and growth [10–12].
NRP-1 also co-interacts with other important heparin-
binding cytokines, such as epithelial growth factor (EGF)
and its receptor (EGFR) [13], and hepatocyte growth fac-
tor (HGF) and its receptor c-Met [14], and activates
these two pathways. The above three cellular signaling
pathways are all shown to be involved in the progression
of gastric cancer [15–18].
It has been reported that NRP-1 is expressed in human
gastric cancer cells and in limited number of human gas-
tric cancer tissues [15]. However, the role of NRP-1 in the
progression of gastric cancer and the related mechanisms
has not been fully elucidated. Gastric cancer is the third
most common cause of cancer-related death in men
worldwide [19]. Conventional adjuvant treatments have
shown only modest effects on the survival of patients with
advanced gastric cancer, and the development of molecu-
lar targeting drugs for gastric cancer is lagging behind
some other cancers [20]. Therefore, it is essential for seek-
ing novel molecular targets for combating gastric cancer.
Here, we designed the present study aiming to investigate
whether NRP-1 expression correlates with the clinicopath-
ologic features of gastric cancer, and whether NRP-1
depletion could inhibit the growth and metastasis of
gastric cancer cells, and whether NRP-1 displays its role
as co-receptors by interacting the VEGF, EGF and HGF-
mediated pathways in gastric cancer cells.
Methods
Patients
A total of 141 consecutive patients with pathologically
proved gastric cancer received curative resection at the
Department of General Surgery, Qingdao Municipal
Hospital in China, between January, 2011 and December,
2013. None of the patients received any preoperative an-
ticancer treatments. Gastric cancer was staged according
to the staging system by the American Joint Committee
on Cancer [21]. The histologic classification of gastric
carcinoma was performed according to the 2010 WHO
histologic classification system and cell differentiation
[21]. This study was approved by the Ethics Committee
of Qingdao Municipal Hospital (Qingdao, China), and
all patients gave their informed consent prior to the
inclusion in the study.
Cell culture, antibodies and reagents
Human gastric cancer cells MGC-803, SGC7901, BGC823,
AGS, NCI-N87 and HGC-27 were obtained from the Type
Culture Collection Cell Bank (Chinese Academy of Sci-
ences Committee, Shanghai, China). Cells were cultured in
RPMI-1640 medium supplemented with 10 % FBS (fetal
bovine serum) at 37 °C in a humidified atmosphere of 5 %
CO2. For antibodies (Abs) and reagents, please refer to
Additional file 1.
Immunohistochemistry of clinical specimens
Formalin-fixed specimens were transferred to 70 % etha-
nol, and subsequently paraffin-embedded, sectioned and
mounted on 3-aminopropyltriethoxysilane-coated slides
(Sigma, Shanghai, China). Antigen retrieval was performed
by heating sections in a microwave in 0.01 M citrate buffer.
Sections were blocked for 2 h, and incubated with a rabbit
anti-human NRP-1 Ab (diluted 1:250) at 4 °C overnight. A
standard horseradish peroxidase staining procedure was
followed using a biotinylated secondary Ab (diluted 1:250,
and immunoreactivity developed with Sigma FAST DAB
(3,3’-diaminobenzidine tetrahydrochloride) and CoCl2
enhancer tablets. Sections were counterstained with
hematoxylin. Normal rabbit sera were diluted 1:10 in PBS,
and used for blocking and dilution of Abs. Negative
controls were achieved by using irrelevant goat IgG at a di-
lution of 1:50. NRP-1 staining was assessed in 20 randomly
selected fields per specimen using a semi-quantitative
grading system, which reflected the proportion and inten-
sity of staining present within the specimen. The staining
intensity (Value A) was graded in a four-tier grading sys-
tem: no staining (0), faint yellow (1), yellow (2) and brown
(3). The extent of positive staining (Value B) was deter-
mined using a four-tier grading system based on the per-
centage of positive cells: ≤ 10 % (1), 11–40 % (2), 41–70 %
(3), and ≥ 70 % (5). The immunohistological score for each
specimen was calculated by A × B, and then each specimen
was graded lower level (≤5) and higher level (>5).
ShRNA expression vectors
The sequence targeting NRP-1 (GAGAGGUCCUGAAUG
UUCC), corresponding to nucleotides 949–967 of human
NRP-1 (GenBank NM_003873.5), was previously reported
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[13]. The chemically synthesized oligonucleotides were
introduced into the pSuppressorNeo vector to generate
NRP-1 shRNA as described previously [22, 23]. A
scrambled shRNA vector (Sc-shRNA) targeting nonspe-
cific sequence (UUCUCCGAACGUGUCACGU) served
as controls.
Establishment of stable transfectants, Cell viability
analysis, Bromodeoxyuridine (BrdU) incorporation assay,
Assessment of cell cycle, Transfection of siRNA, Quantitative
reverse-transcription polymerase chain reaction (qRT-PCR),
Migration assay, Immunoblotting, In situ Ki-67 proliferation
index and Assessment of tumor vascularity
Detailed methods have been described previously [22, 23]
and can be found in Additional file 1.
Animal experiments
Six to 8-week-old male nude BALB/c mice (H-2b) were
obtained from the Animal Research Center, The First
Affiliated Hospital of Harbin Medical University, China.
The experimental protocol was described previously [22,
23]. This study was approved (permit SYXK20020009) by
the Animal Ethics Committee of Harbin Medical Univer-
sity (Harbin, China).
Tumorigenicity study
Cells (2 × 106) were injected subcutaneously into groups
of 10 mice. The animals were monitored every 3 days.
Mice were sacrificed 24 days later, and tumors were
harvested and weighed.
In vivo metastasis study
Cells (1 × 106) were injected into groups of 8 mice via
the tail vein. The mice were sacrificed 7 weeks later.
Lungs were harvested, weighed, then sectioned and
stained by hematoxylin/eosin.
Fig. 1 Expression of NRP-1 in gastric cancer tissues and cells. a-c Representative images of section from gastric normal mucosa (a), adenocarcinoma
(b) and undifferentiated cancer (c), immunostained with an anti-NRP-1 antibody. d Lysates of human gastric cancer cells were immunoblotted. e The
expression of NRP-1 mRNA was analyzed by qRT-PCR, and normalized to β-actin. f The expression of NRP-1 and NRP-2 was examined in lysates of
parental MGC-803, MGC-803-Sc and MGC-803-SURlow cells by immunoblotting. NRP-1 expression in the three cell lines was further detected
by immunohistochemistry
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Therapeutic effect study
Cells (5 × 106) were injected subcutaneously into the
flanks of mice. When tumors reached ~100 mm3, the
mice were assigned to 2 groups of 8 mice, which
received an intratumoral injection of Sc-shRNA or NRP-
1 shRNA, respectively. The shRNA transfection solution
was prepared by mixing shRNA vector, Lipofecta-
mine2000 and serum-free medium. Each tumor received
an injection of 50 μl shRNA transfection solution con-
taining 200 μg shRNA. Two mice from each group were
sacrificed 4 days after intratumoral injection for detect-
ing the expression of NRP-1. Tumors were measured
and mice killed 20 days later.
Statistical analysis
Association between NRP-1 expression and clinicopath-
ologic parameters was analyzed by Mann Whitey test.
Other data are expressed as mean values ± standard
deviation. Comparisons were made with a one-way ana-
lysis of variance (ANOVA) followed by a Dunnet’s test.
P < 0.05 was considered statistically significant.
Results
NRP-1 expression in gastric cancer tissues and its
correlation with clinicopathologic parameters
Normal gastric mucosa had weak NRP-1 expression
(Fig. 1a), whereas gastric cancer tissues expressed different
levels of NRP-1 protein (Table 1). Representatively, gastric
adenocarcinoma (Fig. 1b) expressed relatively lower levels,
while undifferentiated gastric cancer (Fig. 1c), relatively
higher levels of NRP-1. The level of NRP-1 expression was
significantly correlated with clinical staging, tumor differ-
entiation and pathological types of gastric cancer, but not
with patients’ gender and age (Table 1).
NRP-1 expression in gastric cancer cell lines
Human gastric cancer cells expressed different levels of
NRP-1 protein (Fig. 1d), and mRNA (Fig. 1e). MGC-803
cells expressing the highest level of NRP-1 were selected
for generating stable transfectants. MGC-803 cells stably
transfected with NRP-1 shRNA or Sc-shRNA were termed
MGC-803-NRPlow and MGC-803-Sc, respectively (Fig. 1f).
Compared with parental MGC-803 cells, MGC-803-
NRPlow cells expressed significantly lower, while MGC-803-
Sc cells expressed similar, levels of NRP-1. In addition, the
three cell lines expressed similar levels of NRP-2 (Fig. 1f).
NRP-1 depletion inhibits cell growth
MGC-803-NRPlow cells had significantly lower viability,
while MGC-803-Sc cells had the similar viability, com-
pared with parental MGC-803 cells (Fig. 2a). We
examined the expression of cyclin E, CDK2 and p27,
which play key roles in cell proliferation and cycle pro-
gression [24]. The results showed that MGC-803-NRPlow
cells expressed significantly lower levels of cyclin E and
CDK2, and a higher level of p27, than parental MGC-803
cells (Fig. 2b). However, MGC-803-Sc cells expressed
similar levels of the above proteins compared with
parental MGC-803 cells (Fig. 2b). We then examined
cell proliferation by means of BrdU-DAPI staining
(Fig. 2c, d). MGC-803-NRPlow cells had a significantly
lower rate of proliferation than parental MGC-803 cells.
Specifically, 58.5 ± 7.3 % of parental MGC-803 cells, while
only 19.6 ± 3.8 % of MGC-803-NRPlow, were BrdU-
positive (Fig. 2c, d). We further detected cell cycle distri-
bution by flow cytometry. The fraction of cells at the G1
phase was significantly higher in MGC-803-NRPlow cells
compared with parental MGC-803 cells (Fig. 2e, f ).
NRP-1 depletion inhibits cell migration
The number of migrated MGC-803-NRPlow cells was sig-
nificantly lower than that of parental MGC-803 cells
(Fig. 3a, b). It has been reported that NRP-1 interacts the
VEGF/VEGFR2 pathway, resulting in phosphorylation of








Male 87 47 40




<60 93 43 50
≥60 48 29 19
TNM stage 0.019
Stage 0 5 4 1
Stage I 26 20 6
Stage II 38 23 15
Stage III 49 18 31




Tubular 67 38 29
Papillary 42 22 20
Mucinous 13 4 9





Well 35 27 8
Moderate 74 36 38
Poor 32 9 23
Notes: NRP-1, Neuropilin-1. P value was estimated by Mann Whitney test
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FAK, a key factor for cell migration [11]. Here we showed
that MGC-803-NRPlow cells expressed lower, but MGC-
803-Sc cells expressed similar, levels of P-FAK, compared
with parental MGC-803 cells (Fig. 3c). The three cell lines
expressed similar levels of FAK (Fig. 3c).
NRP-1 depletion inhibits tumorigenesis, tumor growth
and metastasis
Based on the in vitro results, we further investigated the
effects of NRP-1 in animal models. Since MGC-803-Sc
cells did not show significant different from parental
Fig. 2 Cell proliferation in vitro. a MGC-803, MGC-803-Sc and MGC-803-NRPlow cells were cultured for 7 days, and their viability measured. b Cellular
expression of NRP-1, p27, cyclin E and CDK2 proteins was detected by immunoblotting. c-f MGC-803 and MGC-803-NRPlow cells were cultured for
4 days. c, d Cell proliferation was analyzed by a BrdU assay. c The percentage of BrdU-positive cells was plotted. d Representative images from the
nuclei of proliferating cells stained green by BrdU, and the nuclei of all cells stained blue by DAPI. Magnification bar = 200 μm. e Cells were subjected
to flow cytometry to measure cell cycle distribution. f The percentages of cells at the G1 phase were plotted. The density of each band was measured
and normalized to β-actin. “*” (P < 0.05) and “**” (P < 0.001) indicate a significant difference from MGC-803 cells
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cells in expression of the above proteins involved in cell
proliferation and migration, we only used parental
MGC-803 cells as controls in the following experiments.
As shown in Fig. 4a, subcutaneous tumors were detected
in 9 out of 10 mice injected with parental MGC-803 cells,
but in only 5 out of 10 mice receiving MGC-803-NRPlow
cells. In addition, MGC-803-NRPlow tumors grew to
761.8 ± 104.3 mm3 (1432.1 ± 209.6 mg in weight), whereas
control MGC-803 tumors reached 1722.4 ± 89.6 mm3
(633.1 ± 90.7 mg in weight), 24 days following cell inocula-
tion (Fig. 4a, b). The mice injected with MGC-803-NRPlow
cells had fewer and smaller metastatic nodules in their
lungs (with an average weight of 235.7 ± 18.5 mg), com-
pared with those injected with parental cells (with an aver-
age weight 378.1 ± 40.3 mg) (Fig. 4c, d). In the study for
testing the therapeutic effects, we established subcuta-
neous tumors by using another gastric cancer cell line,
BGC823, which was also shown to express higher levels
of NRP-1 (Fig. 1d, e). When tumors reached ~
100 mm3, they were injected with either Sc-shRNA or
NRP-1 shRNA. As shown in Fig. 4e, intratumoral deliv-
ery of NRP-1 shRNA resulted in downregulation of
NRP-1 in situ, compared with Sc-shRNA. BGC823 tu-
mors treated with NRP-1 shRNA were significantly
smaller (769.1 ± 82.4 mm3) than those treated with Sc-
shRNA (1521.7 ± 118.5 mm3), 20 days after treatment
started (Fig. 4f ).
NRP-1 depletion inhibits cell proliferation in situ and
tumor angiogenesis
The tumors harvested in Fig. 4b were immunostained
for examining cell proliferation and tumor angiogen-
esis. In consistence with the in vitro results (Fig. 1f ),
MGC-803-NRPlow tumors expressed markedly lower
levels of NRP-1 proteins than MGC-803 tumors
(Fig. 5a). NRP-1 depletion significantly inhibited cell
proliferation and tumoral angiogenesis (Fig. 5a-c). The
expression of key molecules in vivo (Fig. 5d) was con-
sistent with that obtained in vitro.
NRP-1 depletion inhibits VEGF-, EGF- and HGF-activated
pathways
NRP-1 is shown to participate as co-receptors [10–14]
in the activation of the VEGF/VEGFR2, EGF/EGFR and
HGF/c-Met pathways, which play key roles in the prolif-
eration and metastasis of gastric cancer cells [17, 18, 25].
Therefore, we investigated whether depletion of NRP-1
could suppress the activation of these pathways stimu-
lated by respective ligands in gastric cancer cells. MGC-
803 and MGC-803-NRPlow cells were transfected with
Fig. 3 Cell migration. a, b MGC-803 and MGC-803-NRPlow cells were subjected to migration assays, in the presence or absence of 5 % FBS as
chemoattractants. a Migrated cells were visualized using Giemsa staining. Magnification bar = 200 μm. b Numbers of migrating cells were counted.
c MGC-803, MGC-803-Sc and MGC-803-NRPlow cells were immunoblotted to determine the expression of FAK and P-FAK. The density of each band
was measured and normalized to β-actin. “**” (P < 0.001) indicates a significant difference from parental MGC-803 cells
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Fig. 4 Tumorigenesis, metastasis and tumor growth in vivo. a, b MGC-803 and MGC-803-NRPlow cells were subcutaneously inoculated into the mice.
a Tumor volumes were recorded. The number of tumor-bearing mice/ total number of mice are shown in brackets. b Tumors were weighed at the
end of experiments. c, d The above cells were intravenously injected into the mice. The mice were killed 7 weeks later to harvest the lungs, which were
sectioned and stained by hematoxylin/eosin (c), and weighed (d). e, f BGC823 tumors were established in mice, and injected with control Sc-shRNA or
NRP-1 shRNA when they reached ~100 mm3 in volume. e Illustrated are representative tumor sections prepared 4 days following intratumoral injection.
NRP-1 was immunostained brown by an anti-NRP-1 Ab. Magnification × 400. f The sizes of tumors were measured. “n” indicates the number of tumors.
“*” indicates P < 0.05, and “**”, P < 0.001
Li et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:16 Page 7 of 12
siRNAs targeting VEGFR2, EGFR and c-Met, and then
incubated with recombinant human VEGF-165, EGF
and HGF proteins, respectively. Transfection of siRNAs
targeting VEGFR2, EGFR and c-Met resulted in mark-
edly downregulation of VEGFR2, EGFR and c-Met, but
had no effect on the expression of NRP-1, in both
MGC-803 and MGC-803-NRPlow cells (Fig. 6a-c).
Incubation of recombinant VEGF-165 protein had no
effect on the expression of NRP-1 or VEGFR2, but
markedly increased the levels of P-FAK, a downstream
Fig. 5 Tumoral angiogenesis and cell proliferation in situ. a Illustrated are representative sections prepared from tumors in Fig. 4b. Sections were
stained with antibodies against NRP-1 (left panel), Ki67 (middle panel) or CD31 (right panel). The cell proliferation index (b) and microvessel density
(c) were quantified. “n” indicates the number of tumors examined. d Homogenates prepared from tumors in Fig. 4b were immunoblotted. The density
of each band was measured and normalized to that of β-actin. “*” (P < 0.05) and “**” (P < 0.001) indicate a significant difference from MGC-803 tumors
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factor of VEGFR2 pathways [11], in MGC-803 and MGC-
803-NRPlow cells (Fig. 6a). Transfection of VEGFR2 siRNA
significantly reduced the level of P-FAK in MGC-803 and
MGC-803-NRPlow cells (Fig. 6a). The level of P-FAK was
significantly lower in MGC-803-NRPlow cells than MGC-
803 cells, when they received the same treatments, either
untreated, incubation with VEGF-165 protein, transfection
with VEGFR2 siRNA, or the combination (Fig. 6a).
NRP-1 regulates the EGFR signaling pathways, resulting
in activation of downstream signaling cascades including
the MEK/ERK pathway [13]. Here we showed that incuba-
tion of recombinant EGF protein had no effect on the ex-
pression of NRP-1 or EGFR, but increased the levels of P-
MEK and P-ERK proteins in parental MGC-803 and
MGC-803-NRPlow cells (Fig. 6b). EGFR siRNA transfec-
tion significantly inhibited the expression of P-MEK and
P-ERK in parental MGC-803 cells and MGC-803-NRPlow
cells (Fig. 6b). The levels of P-MEK and P-ERK were sig-
nificantly lower in MGC-803-NRPlow cells than MGC-803
cells, when they received the same treatments, either
untreated, incubation with EGF protein, transfection with
EGFR siRNA, or the combination (Fig. 6b).
The HGF/c-Met pathway is involved in the progression
of gastric cancer by activating Akt pathways [18]. Here we
demonstrated that incubation of recombinant HGF protein
had no effect on the expression of NRP-1 or c-Met, but in-
creased the levels of P-Akt and reduced the levels of p27 in
parental MGC-803 and MGC-803-NRPlow cells (Fig. 6c).
Fig. 6 NRP-1 depletion influences the activation of VEGF/VEGFR2, EGF/EGFR and HGF/c-MET pathways. MGC-803 and MGC-803-NRPlow cells were
transfected with siRNAs targeting VEGFR2 (a), EGFR (b) or c-MET (c). The cells were then cultured for 24 h in the presence or absence 100 ng/ml
of recombinant VEGF-165 (a), of 10 ng/ml of recombinant EGF (b) or 100 ng/ml of recombinant HGF (c) proteins, respectively. Cell lysates were
immunoblotted to determine the expression of key proteins involved in the above pathways as indicated. The density of each band was measured
and normalized to β-actin. “*” indicates P < 0.05, and “**”, P < 0.001. “#” (P < 0.05) and “##” (P < 0.001) indicate a significant increase, and “†” (P < 0.05)
and “††” (P < 0.001), a significant reduction, from untreated respective cells. “ϕ” (P < 0.05) and “ϕϕ” (P < 0.001) indicate a significant difference from
MGC-803 cells with the same treatments
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Transfection of c-Met siRNA significantly downregulated
the expression of P-Akt but increased the expression of
p27 in parental MGC-803 cells and MGC-803-NRPlow
cells (Fig. 6c). The levels of P-Akt were significantly lower,
while the levels of p27 were significantly higher, in MGC-
803-NRPlow cells than MGC-803 cells, when they received
the same treatments, either untreated, incubation with
HGF protein, transfection with c-Met siRNA, or the com-
bination (Fig. 6c).
Discussion
NRP-1 has been shown to participate in the proliferation
of cells from hepatocellular carcinoma [2], lung cancer [6],
leukemia and lymphoma [8] and medulloblastoma [9]. In
accord, the present results have demonstrated that deple-
tion of NRP-1 inhibited the proliferation of gastric cancer
cells by inducing cell cycle arrest in the G1/S phase
through upregulating p27 and downregulating cyclin E and
CDK2. P27 is implicated in the negative regulation of cell
cycle progression from G1 to S phase by binding to and
modulating the activity of CDKs [24]. Conversely, the cyc-
lin E/CDK2 complex promotes progression from G1 to S
phase by triggering the initiation of DNA replication [24].
Distant metastasis is the leading cause of mortality for
gastric cancer, and is a major treatment obstacle [21]. Anti-
angiogenic therapy, such as VEGF inhibition, continues to
be a focus for developing anticancer drugs for gastric
cancer [16]. However, VEGF inhibition demonstrates only
transient and invariable benefits, and can also induce
hypertension and renal toxicity due to its off-target effects
by blocking the cellular signaling of VEGFR1 [26]. The rec-
ognition that NRP-1 is engaged by specific VEGF isoforms
has expanded the landscape for developing modulators of
VEGF-dependent signaling [27]. Here we showed that
NRP-1 depletion inhibited VEGF-activated VEGF/VEGFR2
pathway, which is crucial for tumor angiogenesis by regu-
lating the phosphorylation of FAK [28], a key factor in cell
migration and metastasis [29]. In support of our results,
blockage of NRP-1 inhibited tumor growth and VEGF-
mediated angiogenesis [11]. The VEGF/NRP-1 pathway is
also involved in cancer cell proliferation by activating Akt,
leading to sequential p27 downregulation [30].
NRP-1 interacts with EGFR and promotes its signaling
cascade elicited upon EGF stimulation in cancer cells [13].
The EGF/EGFR pathway is involved in the progression of
gastric cancer [17]. In accord, the present study has
Fig. 7 NRP-1 structure and a proposed model of interactions of NRP-1 as multifunctional co-receptors with VEGF/VEGFR2, EGF/EGFR and HGF/c-MET
pathways in gastric cancer cells. NRP-1 molecule consists of five extracellular domains, a single-pass transmembrane domain (TMD) and a short
cytosolic tail. “→” indicates promotion, positive regulation or activation; “⊥”, inhibition, negative regulation or blockade. A dotted line indicates
uncertain mechanisms, while a solid line, identified mechanisms. Abbreviations: CDK, cyclin-dependent kinase; EGF, epithelial growth factor;
EGFR, epithelial growth factor receptor; ERK, extracellular-signal-regulated kinase; FAK, focal adhesion kinase; HGF, hepatocyte growth factor; MEK,
mitogen-activated protein kinase; NRP-1, neuropilin-1; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor
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demonstrated that NRP-1 silencing counteracted ligand-
induced EGFR activation, evidenced by the reduced phos-
phorylation of MEK and ERK, two downstream factors of
the EGFR pathway [31]. The MEK/ERK pathway partici-
pates in the progression of gastric cancer by contributing
to cell proliferation and metastasis [17, 32].
NRP-1 is also implicated in the activation of HGF-
induced signaling and cellular responses in cancer cells
[14]. The involvement of HGF/c-Met pathway leads to
the activation of PI3K/Akt signaling pathway in gastric
cancer cells [18]. Accordingly, we have demonstrated
herein that NRP-1 depletion attenuated HGF-stimulated
the activation of HGF signaling pathway, evidenced by
reduced activation of Akt.
The general domain structure of NRP-1 [1] and proposed
mechanisms for its role as co-receptors in the proliferation
and metastasis of gastric cancer cells are summarized in
Fig. 7. NRP-1 co-interacts with VEGF/VEGFR2 [10–12],
EGF/EGFR [13] and HGF/c-Met [14] pathways. The activa-
tion of the VEGFR2 pathway results in the phosphorylation
of FAK, which promotes cell metastasis [11, 28]. The
activation of the c-Met pathway induces sequential
activation of Akt [25], which in turn leads to down-
regulation of p27 [24, 33]. P27 negatively regulates
cell cycle progression by modulating the activity of
CDK2/cyclin E complex [24]. The activation of EGFR
pathway leads to the phosphorylation of MEK and
ERK, which contributes to the proliferation and me-
tastasis of gastric cancer cells [17, 32]. Although not
investigated in the present study, the cross-talks among
the above signaling pathways may also be involved in can-
cer cell proliferation and metastasis [31].
Conclusions
In summary, NRP-1 is overexpressed in gastric cancer tis-
sues, and its expression correlates with the clinical staging,
tumor differentiation and pathological types of gastric can-
cer. NRP-1 depletion inhibited the proliferation and migra-
tion of gastric cancer cells, and suppressed their ability to
form tumors and to metastasize to lungs, and therapeutic
NRP-1 shRNA inhibited the growth of established gastric
tumors in experimental animals. NRP-1 depletion counter-
acted the activation of VEGF/VEGFR2, EGF/EGFR and
HGF/c-Met pathways stimulated by respective ligands,
indicating that NRP-1 acts as multifunctional co-receptors
in gastric cancer cells. Taken together, the present results
suggest that NRP-1 may be a valuable biomarker and po-
tential therapeutic target for gastric cancer, particularly for
those expressing higher levels of NRP-1.
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